Does Hepatitis C Still Remain An Epidemic With Financial Concerns?

Every patient who gets to know his suffering with the introduction of a new set of HCV virus into his/her blood stream asks a similar set of question i.e. whether the medication to the cure is accessible and within reach or not?

During the early times, people used to bother a lot in case a person was identified to be suffering from it. But, during that time situations were totally different! The disease was known but, the cure wasn’t, so it was a sure shot death concerns approaching an infected person. Scarcity and scare of the approaching death, people used to call the disease as a dreadful disease.

With the advent of modern medicine and rigorously conducted researches, a number of efficient medicines came into being. The introduction of these medicines like- Sofosbuvir, hepcinat tablets 400mg, etc. situations changed, completely. With hopes in eyes, patients knew they could get healed and live longer and healthy, too.

The question however, still remains around asking- does hepatitis c still remain a financial epidemic?

Many of the medicines today are pretty affordable as per the condition and stage of hepatitis C entered by the patient. Ledipasvir, sofosbuvir, Hepcinat, etc. are the top examples of the same but; still there are a number of countries that often fall subject to denials in case of hepatitis C diagnosis and medication.

The number of insurance denials for obtaining the life-saving hepatitis C drugs has been high across countries like US. However, it remains pretty affordable in India.

Patients are subject to denials from both private and public insurers. Many of the statistical studies have reported the same. In fact, as per a study conducted by researchers from the Perelman School of Medicine at the University of Pennsylvania reported that following have been denial rates-

  • Specially, the private insurers have scored the highest denial rates of 52.4%
  • Medicaid has denied 34.5% of the patients
  • Medicare have denied 14.7% of the patients


After obtaining a 95% cure rate in US, such denials tend to be surprising. However, the prime reason behind the same is mainly due to the ranging cost of medication in these countries that tends to be between $40,000 and $100,000. This is why both the private and public insurers have denied such approvals.

Don’t you think this is less than an epidemic?

India tends to be at a better position with such concerns due to the easy and affordable availability of all such medicines at the best prices. Anandmedicos is one such name in the world of medical aid for hepatitis C in India. Offering all sorts of hepatitis C medicines right from Hepcinat Tablets 400mg, Ledipasvir and sofosbuvir combination medicines and many other generic and combination medicines, they have raised the bar pretty high yet pretty pocket-friendly.